Patents Assigned to Merck
  • BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS
    Publication number: 20240409531
    Abstract: The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: October 10, 2022
    Publication date: December 12, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Abdellatif El Marrouni, Antonella Converso, Ashley Forster
  • NANOEMULSION ADJUVANT COMPOSITIONS FOR HUMAN PAPILLOMAVIRUS VACCINES
    Publication number: 20240408188
    Abstract: The present disclosure provides, among other things, a vaccine composition that includes a squalene nanoemulsion (SNE) adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
    Type: Application
    Filed: June 6, 2024
    Publication date: December 12, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick L. Ahl, William J. Smith, Randal J. Soukup, Nicole Lea Sullivan, John Gaspar, Julie M. Skinner
  • PHARMACEUTICAL FORMULATION
    Publication number: 20240408021
    Abstract: The present invention relates to a pharmaceutical formulation of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof, as well as a method of making same, as well as medical uses thereof.
    Type: Application
    Filed: August 21, 2024
    Publication date: December 12, 2024
    Applicant: Merck Patent GmbH
    Inventors: Simon Geissler, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
  • Process for the production of a molecular layer and electronic component comprising same
    Patent number: 12163223
    Abstract: A process is described for production of a molecular layer on a substrate using atomic layer deposition (ALD) techniques, for use in electronic components, in particular, in memory elements of the ReRAM type. Additionally, compounds for production of the molecular layer are disclosed, as well as memory elements containing the molecular layer.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: December 10, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Sebastian Resch, Henning Seim, Jacob Woodruff, Charith Nanayakkara
  • Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
    Patent number: 12161721
    Abstract: The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Patrick McHugh, Michael Albert Winters, Janelle Konietzko
  • Reactive mesogens
    Patent number: 12162834
    Abstract: Reactive mesogens (RMs), mixtures and formulations comprising RMs, polymers obtained from such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices, like optical films for liquid crystal displays (LCDs).
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: December 10, 2024
    Assignee: Merck Patent GmbH
    Inventors: Jack Bradford, Kevin Adlem, Naomi Weare, Vicki Poole, Iain Gardiner
  • Liquid-crystal medium
    Patent number: 12163081
    Abstract: A liquid-crystal (LC) medium based on a mixture of polar compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the vertically aligned mode, to an LC display of the vertically aligned mode containing the LC medium, especially an energy-saving LC display and a process of manufacturing the LC display.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: December 10, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Harald Hirschmann, Sabine Schoen, Philipp Wucher
  • Purification process for removal of tyrosine sulfation antibody variants; purified compositions
    Patent number: 12162938
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
    Patent number: 12162883
    Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 10, 2024
    Assignees: Merck Sharp & Dohme LLC, Merck Sharp & Dohme (UK)
    Inventors: John Y. L. Chung, Tetsuji Itoh, Jungchul Kim, Jacob Henry Waldman, Debra J. Wallace, Andrew Wood, Feng Xu, Andrew Gibson, Jeremy Peter Scott
  • ADDITIVES FOR PROTEIN FORMULATIONS TO IMPROVE THERMAL STABILITY
    Publication number: 20240398957
    Abstract: The present invention relates to excipients for special protein formulations, which are suitable to improve the thermal stability against denaturation and deactivation. In particular, the present invention relates to additives for thermostabilizing of vaccine formulations.
    Type: Application
    Filed: July 25, 2024
    Publication date: December 5, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Tobias ROSENKRANZ, Janet SCHACHE
  • POLYMERISABLE COMPOUND, POLYMERISABLE LC MATERIAL AND POLYMER FILM
    Publication number: 20240400900
    Abstract: A polymerisable liquid crystal (LC) compound, a corresponding polymerizable LC material, a polymer film with flat, negative, or positive optical dispersion obtainable from such a material, and the use of the polymerisable LC, polymerisable LC material and/or polymer film in optical, electro optical, electronic, semiconducting, or luminescent components or devices.
    Type: Application
    Filed: October 10, 2022
    Publication date: December 5, 2024
    Applicant: MERCK PATENT GmbH
    Inventors: Kevin Adlem, Martin Heeney, James Allen
  • C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240398784
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: September 26, 2022
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Luis Torres, Xin Yan
  • COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20240398925
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
    Type: Application
    Filed: August 22, 2024
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
  • 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3
    Publication number: 20240400571
    Abstract: Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
    Type: Application
    Filed: May 30, 2024
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Zachary G. Brill, Chen Cheng, Donna A.A.W. Hayes, Kyle S. McClymont, Rohan Rajiv Merchant, Maoqun Tian
  • NEW STABLE SALT OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID
    Publication number: 20240400574
    Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Application
    Filed: August 9, 2024
    Publication date: December 5, 2024
    Applicant: MERCK & CIE
    Inventors: Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
  • TRICYCLIC SULFAMIDES AND SULTAMS
    Publication number: 20240400583
    Abstract: Compounds of formula I, that modulate DCAF15 and induce RBM139 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity and DCAF15 modulation are described herein.
    Type: Application
    Filed: October 7, 2022
    Publication date: December 5, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John P. Caldwell, Ping Lan, Hongwu Wang, Paul Wehn
  • Combination therapies for treating cancer
    Patent number: 12156872
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: December 3, 2024
    Assignees: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 12157727
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 3, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang, Wensheng Yu, Brett A. Hopkins, Xavier Fradera, Nunzio Sciammetta
  • COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES
    Publication number: 20240390471
    Abstract: The invention relates to novel compounds and formulations. Further, the invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the invention relates to compositions comprising pneumococcal conjugates and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, prepared as stable nanoemulsions (herein referred to as “SNE adjuvant compositions” or “SNEs”).
    Type: Application
    Filed: May 16, 2024
    Publication date: November 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick L. Ahl, Peter J. Manley, Izzat T. Raheem, W. Michael Seganish, William J. Smith
  • Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 12152019
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 26, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu